New agents for bladder cancer

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Bellmunt, J ^a   Guix, M ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Bladder cancer; Chemotherapy; Targeted therapies; Transitional cell carcinoma; Urothelial tumors

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4877; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IXABEPILONE; LAPATINIB; LAROTAXEL; METHOTREXATE; PACLITAXEL; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; GRANULOCYTOPENIA; HUMAN; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DRUGS, INVESTIGATIONAL; HUMANS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 78649369433     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq367     Document Type: Conference Paper

References (13)

1. von der Maase H, Sengelov L, Roberts JT et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602.
2. Philips GK, Halabi S, Sanford BL et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009; 20: 1074-1079.
3. Bellmunt J, Albiol S, Suá rez C et al. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol/Hematol 2009; 69: 211.
4. Tomlinson DC, Baldo O, Harnden P et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91-98.
5. Bernard-Pierrot I, Brams A, Dunois-Larde C et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006; 27: 740-747.
6. Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2009; 28: 1373-1379.
7. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24: 3451.
8. von der Maase H, Lehmann J, Gravis G et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 2006; 17: 1535.
9. Galsky MD, Mironov S, Iasonos A et al. Phase II trial of pemetrexed as secondline therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25: 265-270.
10. Dreicer R, Li S, Manola J et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007; 110: 759.
11. Vaughn DJ, Srinivas S, Stadler WM et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115: 4110.
12. Culine S, Theodore C, De Santis M et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94: 1395.
13. Bellmunt J, Thé odore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454.